AstraZeneca's targeted drug Tagrisso India is approved for adjuvant treatment of early EG...

AstraZeneca India recently announced that the targeted anticancer drug Tagrisso (Chinese trade name: Teresa, generic name: osimertinib, osimertinib) has been approved in India: for tumors carrying epidermal growth factor receptors (EGFR) mutated non-small cell lung cancer (NSCLC) patients with adjuvant treatment after complete tumor resection.

Lung cancer is an extremely aggressive and devastating cancer.

Tagrisso is a once-daily oral pill that is used to treat patients whose tumors carry EGFR mutations (EGFRm) and have undergone lung cancer surgery.

It is particularly worth mentioning that the ADAURA trial is the first global clinical trial to evaluate the statistically significant and clinically significant benefits of an EGFR inhibitor in the adjuvant treatment of lung cancer.

ADAURA is a randomized, double-blind, global, placebo-controlled Phase III study, conducted in 682 early (IB/II/IIIA) EGFRm-NSCLC patients who have received complete tumor resection and optional Standard postoperative adjuvant chemotherapy has evaluated the efficacy and safety of Tagrisso for adjuvant therapy.

The main results of the study were published in the New England Journal of Medicine in September 2020.

Based on the unprecedented efficacy results of the ADAURA study, the U.

In January of this year, AstraZeneca announced the results of an exploratory analysis of the ADAURA study at the 2020 21st World Lung Cancer Conference (WCLC) online conference hosted by the International Association for the Study of Lung Cancer.

Tagrisso is the third-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which can overcome the resistance of the first and second-generation EGFR-TKI of this class of drugs, including Roche/Astellas Tarveca (Tarveca), AstraZeneca Iressa (Iressa), Boehringer Ingelheim Gilotrif (afatinib, afatinib).

Tagrisso can inhibit EGFR sensitive mutations and EGFR-T790M resistant mutations, and has clinical activity against central nervous system metastasis.

Currently, AstraZeneca is developing Tagrisso for locally advanced unresectable disease (LAURA study), combined with chemotherapy to treat metastatic disease (FLAURA2), and combined with potential new drugs to solve EGFR TKI resistance (SAVANNAH study, ORCHARD study) .

Original source: AstraZeneca receives marketing authorisation for Tagrisso (Osimertinib) for adjuvant treatment of EGFRm Non-Small Cell Lung Cancer (NSCLC) in India

This article is from Bio Valley, for more information, please download the Bio Valley APP (http://